相关实验视频
Updated: Jul 8, 2025

06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
622
梅特福林对心脏参数的影响,非糖尿病的伊拉克患者心力衰竭和中等射出分数 - - 一个比较的双臂并行临床研究
Reeman Sabbar1, Sinaa Abdul Amir Kadhim1, Hayder Adnan Fawzi2
1Department of Pharmacology, College of Medicine, University of Al-Qadisiyah, Al-Qadisiyah, Iraq.
Journal of medicine and life
|December 18, 2023
概括
糖尿病药物梅特福明通过增加射出分数和降低N-终端亲BNP (NT-proBNP) 水平,显著改善了心力衰竭 (HF) 患者的心脏功能.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一个重要的医疗保健挑战,需要有效的干预措施.
- 甲胺主要是一种糖尿病药物,在HF管理中显示出潜在的治疗益处.
研究的目的:
- 为了评估添加甲福林到标准HF治疗对关键心脏参数的影响.
- 评估甲福明对HF患者心脏功能和生物标志物的影响.
主要方法:
- 一项随机临床研究,涉及60名新诊断HF患者.
- 患者被分为两组:标准的HF护理 (C组) 和标准的护理加每天500毫克的甲福林 (M组).
- 在3个月的治疗期后,评估了心脏参数和生物标志物.
主要成果:
- 与C组相比,M组的射出分数 (EF) 显著增加 (6.1%对3.2%,p=0.023).
- 在M组 (p=0.029) 观察到左心室末端透气压 (LVEDD) 的显著降低.
- 与C组相比,M组的N-终端亲BNP (NT-proBNP) 水平显著降低 (p=0.009).
结论:
- 甲福明在HF患者中表现出心脏保护作用,增强EF并减少NT-proBNP.
- 梅特福林的价格和可获得性使其成为心力衰竭的有价值的潜在辅助疗法.
- 进一步的研究可能会阐明甲胺增强常规HF治疗的机制.
关键词:
ACEI: ангиотензин转化酶 (ACE) 抑制剂AMPK:腺单酸盐激活蛋白激酶.阿尔尼:抗素受体/尼普利利辛抑制剂.体重指数 (BMI):身体质量指数.EF:喷射小部分.心声回声扫描 (Echocardiography) 是一种心声回声扫描.HF:心脏衰竭是什么意思HFmrEF:心力衰竭与中等范围的喷射分数.HbA1C:糖化血红蛋白A1C 糖化血红蛋白 A1C 糖化血红蛋白心脏衰竭是因为心脏衰竭.IVST:心室间隔隔膜的厚度LV:左心室的左心室.LVEDD:左心室末端的透析直径.LVESD:左心室末端缩直径甲胺是一种甲胺.在 N-终端 proBNP 中.NT-proBNP:N 终端亲大脑尿性.ST2:可溶性抑制瘤发生性 2T2DM:第二种类型的糖尿病.相关概念视频
Heart Failure Drugs: Diuretics
395
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207

